CF PHARMTECH (02652) rose more than 5%. At the time of writing, the stock was up 3.34%, trading at HK$21.64 with a turnover of HK$10.7456 million.

On the news front, on April 27, CF PHARMTECH announced a key clinical advancement in the field of respiratory interventional medical device therapy. The first patient in the clinical trial for its self-developed endobronchial valve (EBV), used to treat severe emphysema, showed positive postoperative outcomes and has successfully completed the clinical observation period, exiting the study group. This progress signifies the company's achievement of a systematic pipeline layout extending from inhaled drugs to interventional devices.

The successful completion of clinical trial treatment and discharge for the first patient represents a major milestone in the EBV project's development and provides valuable experience for advancing subsequent clinical trials.

As an integrated innovative pharmaceutical company focused on the R&D, production, and commercialization of inhaled formulations and treatments for respiratory diseases, CF PHARMTECH has established a product matrix covering multiple conditions, including asthma, COPD, and allergic rhinitis. The company possesses five core technology platforms: particle engineering, device design, product performance evaluation, clinical development, and process engineering, which support the simultaneous development of innovative drugs and devices.

The steady progress of the EBV project enables the company to extend from inhaled drug therapies to interventional device treatments, building a comprehensive disease management solution that covers pharmaceutical intervention for mild-to-moderate diseases and device intervention for severe conditions. This further strengthens its integrated positioning in the respiratory disease treatment sector.